Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC.

Community Practice Connections™: Improving Prognosis in SSc-ILD: Best Practices in Diagnosis, Optimizing Clinical Management, and Efficient Patient Communication

Access Activity

Overview / Abstract:

Target Audience

This activity is intended for pulmonologists and critical care specialists. Rheumatologists, dermatologists, clinical immunologists, allergists, primary care clinicians, nurses, nurse practitioners, physician assistants, and other specialists interested in the treatment of patients with SSc-ILD are also invited to participate in the educational curriculum.

Activity Overview

Interstitial lung disease (ILD) is a frequent and debilitating complication of systemic sclerosis (SSc), affecting up to 90% of patients diagnosed with SSc. SSc-ILD is a pulmonary fibrosing disorder characterized by systemic inflammation, progressive scarring of the lungs, and eventual respiratory failure. Patients diagnosed with SSc need regular screening for ILD because early detection of progressive lung involvement is critical to achieving the most efficacious response to pharmacologic intervention, which is more beneficial in the early stage of disease. Therapy was previously limited, but 3 agents have recently received approval with specific indications for SSc-ILD.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the virtual symposium held at the American Thoracic Society Meeting in May 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with systemic sclerosis who are at risk for development of ILD, putting recent clinical trial data into clinical context. The program is designed to provide education for those who did not attend the virtual meeting and to help reinforce learnings for those who did.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

Review the pathophysiology of SSc-ILD and the implications that new insights have for diagnosing and treating the disease
Recognize key risk factors and diagnostic tests that could improve early symptom recognition and prognosis of the disease.
Evaluate key data on new and emerging treatment options for SSc-ILD to properly educate patients.
Implement team-based strategies to improve individualization of treatment plans for patients with SSc-ILD.

Expiration

Jun 29, 2022

Discipline(s)

Nursing CNE, Physician CME

Format

Online

Credits / Hours

1.0 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
Steven Nathan, MD
Medical Director, Advanced Lung Disease and Lung Transplant Program
Inova Fairfax Hospital
Falls Church, VA

FACULTY_NAME
Kristin Highland, MD, MSCR
Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH

FACULTY_NAME
Justin Oldham, MD, MS
Assistant Professor of Medicine
Director, Interstitial Lung Disease Program
University of California, Davis
Davis, CA

FACULTY_NAME
Joshua Solomon, MD
Associate Professor of Medicine
Autoimmune Lung Center and Interstitial Lung Disease Program
National Jewish Health
Denver, CO

Sponsors / Supporters / Grant Providers

Physicians’ Education Resource®, LLC.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., SSc-ILD Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map